📰 Aktx News
Page 4 - Aktx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Aktx. Real-time updates on events, politics, business and more.
April 26, 2023
StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance NASDAQ AKTX opened at $0.19 on Friday. The stock has a 50-day simple moving average of $0.26 and a two-hundred […]
April 17, 2023
StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Up 5.3 % Shares of AKTX opened at $0.20 on Friday. The stock has a market cap of $14.90 million, a […]
April 2, 2023
StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report sent to investors on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright assumed coverage on Akari Therapeutics in a research report on Monday, December 5th. They set a buy rating and […]
March 31, 2023
Research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright assumed coverage on Akari Therapeutics in a report on Monday, December 5th. They set a “buy” rating and a […]
March 24, 2023
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report issued on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright started coverage on Akari Therapeutics in a research report on Monday, December 5th. They set a buy rating and a $1.50 price objective […]
April 13, 2022
StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock. NASDAQ:AKTX opened at $1.13 on Monday. Akari Therapeutics has a 1-year low of $1.05 and a 1-year high of $2.74. The firm has a fifty day […]
March 21, 2022
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report published on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock. NASDAQ AKTX opened at $1.10 on Friday. Akari Therapeutics has a 52 week low of $1.05 and a 52 week high of $3.20. The stock has […]